Johnson & Johnson vs. Pfizer; Which pharmaceutical stocks are the most suitable for investment in 2026?

Source link: Johnson & Johnson vs. Pfizer; Which pharmaceutical stocks are the most suitable for investment in 2026? In the health care stock market, Johnson & Johnson and Pfizer offer two different paths to investors. Johnson & Johnson has diversified income and sales growth by simultaneously operating in medicine and medical equipment. In contrast, Pfizer is attractive to income-oriented investors with a cash dividend yield of nearly 6%.

In the health care stock market, Johnson & Johnson and Pfizer offer two different paths to investors. Johnson & Johnson, with the simultaneous activity of the Federal Reserve member's warning about inflationary expectations; Hemek emphasized the necessity of further monetary contraction. Hemek, a member of the Federal Reserve, announced that there are early warning signs of a possible problem in inflation expectations, and Mohsen Rezaei, the secretary of Iran's Supreme National Security Council: We will not return to the way we pursued diplomacy in the past. America's response to Iran's conditions for ending the war is "insufficient".

Fitch rating agency has warned that France's A+ credit rating is under the pressure of increasing government debt, weak economic growth, and OPEC+ ministers met on the sidelines of the Riyadh conference. OPEC+ ministers emphasized the importance of protecting international shipping routes to ensure the continuity of energy supply. The current disruption in Meta has unveiled a new artificial intelligence model to compete with OpenAI and Anthropic Meta Company ($META) has released a new artificial intelligence model called Muse Wonder, which according to the company, you can find out about the news by subscribing to the YouTube Times newsletter.

In the health care stock market, Johnson & Johnson and Pfizer offer two different paths to investors. Johnson & Johnson has diversified income and sales growth by simultaneously operating in medicine and medical equipment. In contrast, Pfizer is attractive to income-oriented investors with a cash dividend yield of nearly 6%. However, the end of exclusive support for important drugs and pressure on future earnings will complicate the valuation of these two companies.

Johnson & Johnson operates in two main segments: Innovative Medicines and Medical Technologies. In fiscal year 2025, the sales of these two segments were 60.4 and 33.8 billion dollars, respectively. The company's total revenue reached 94.2 billion dollars with a growth of about 6%, and its net profit was reported at 26.8 billion dollars. However, this profit was affected by the reversal of approximately $7 billion in talcum powder-related litigation reserves, and should not be attributed entirely to the company's repeatable operating performance.

In the second quarter of 2026, the company's sales increased by 6.6% and reached $25.3 billion. Management also raised its annual sales forecast to $100.8 billion to $101.4 billion. The annual increase in cash profit for the 64th consecutive year is also a significant record. However, lawsuits related to talc and competitive pressure on some drugs are still important risks for the company.

Pfizer's revenue reached 62.6 billion dollars in 2025 with a drop of about 1.6%. In the second quarter of 2026, this company recorded a growth of about 3% in revenue and its sales reached 15 billion dollars; However, it reported a net loss of $248 million due to the recognition of $4.3 billion in impairment of intangible assets.

Pfizer's annual cash dividend is $1.72 per share, which creates a yield of about 6.1% based on the price mentioned in the report. This rate is much higher than Johnson & Johnson's yield of about 2%. However, from 2026 to 2030, Pfizer expects expiring patents and legal exclusivity protections to significantly pressure revenue from its products. The obesity drug programs acquired through the acquisition of Metsera are still in the clinical development stage and the compensation for this revenue loss is not certain.

"From an analytical perspective, Pfizer's 6% cash dividend yield alone is not a sign of value; The decisive criterion is the company's ability to maintain free cash flow after the decline in proprietary drug revenue. Johnson & Johnson is also not without risk in higher valuation and legal obligations despite the more appropriate operational quality. Therefore, the evaluation of these two stocks should be done based on the stability of cash flow, the quality of earnings and the ability to replace expiring products, not just comparing the cash dividend yield or the price-to-earnings ratio.

Valuation figures and cash dividend yield are based on the data in the report and may change with changes in stock prices and profit forecasts. Pfizer's lower ratios don't necessarily mean definitive value; Because the market may have reflected part of the risk of future income decline in its price.

Johnson & Johnson presents a more stable picture in terms of sales growth, business diversification and a track record of increasing cash dividends; In contrast, Pfizer is worth checking out for investors looking for high cash income and a lower valuation. The choice between these two companies depends on the investment horizon, risk tolerance and future profit stability.

Artificial intelligence has been used to translate some parts of this report.